Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: An Update from ASCO 2022

PCE

In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include:

• Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLC
• Updated survival and safety results after 5 years from the phase III Checkmate 227 study of nivolumab and ipilimumab vs chemotherapy in previously untreated advanced NSCLC, including assessment of a treatment-free interval
• Updated analysis from the phase III ATEZO-BRAIN trial of atezolizumab + carboplatin and pemetrexed in patients with advanced NSCLC with untreated brain metastases
• Updated overall response analysis from the phase II KEYNOTE-799 study of pembrolizumab with concurrent chemoradiation in unresectable, locally advanced stage III NSCLC
• Results from a phase II trial evaluating nivolumab plus ipilimumab vs nivolumab monotherapy following chemoradiation in unresectable stage III NSCLC
• Pathological complete response results from the phase II NADIM II study of nivolumab and chemotherapy vs chemotherapy in the neoadjuvant NSCLC setting

Presenter:

Beth Sandy, MSN, CRNP
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program:
https://bit.ly/39vuCHC